APP and Alzheimer disease: In addition, an untargeted lipidomics study carried out in APP/PS1 transgenic mice have shown the decrease of PCs (p-16:0/18:3, 14:0/16:0, and 18:0/24:1) in plasma and brain of mice at the ages of 2, 3, and 7 months (64); and the levels of PCs (16:0/20:5, 16:0/22:6, and 18:0/22:6) (65) and PCs (36:6, 38:0, 38:6, 40:1, 40:2, and 40:6) (66) were found decreased in plasma from AD patients.